Loading organizations...
Developing targeted conjugated anti-tumor drugs using innovative designs.
Ascentawits has raised $29.8M across 2 funding rounds.
Ascentawits has raised $29.8M in total across 2 funding rounds.
Ascentawits has raised $29.8M in total across 2 funding rounds.
Ascentawits's investors include Sangel Capital, Guozhong Capital.
Ascentawits has raised $29.8M across 2 funding rounds. Most recently, it raised $15.5M Pre-Series B in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 11, 2021 | $15.5M Pre-Series B | Sangel Capital | |
| Feb 28, 2020 | $14.3M Series A | Guozhong Capital |